Targeting Cardiac Fibrosis Through RNA Regulation: HTX-001 Receives FDA Fast Track Designation

Although nonobstructive hypertrophic cardiomyopathy does not involve significant left ventricular outflow tract obstruction, thickened, stiff, and progressively fibrotic heart muscle can still cause difficulty breathing and fatigue, and may even lead to heart failure. Now, an RNA therapy that does not act directly on cardiac contractile proteins but instead seeks to reprogram the state of fibrotic cells has received a designation from a U.S. regulator intended to expedite development.

HAYA Therapeutics announced on July 28 that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to HTX-001 for symptomatic nonobstructive hypertrophic cardiomyopathy. This designation is not marketing approval and does not mean efficacy has been confirmed. Its primary purpose is to allow the developer to communicate more frequently with the FDA and may enable arrangements such as rolling submission, Priority Review, or Accelerated Approval if other conditions are met.

HTX-001 is an antisense oligonucleotide targeting a long noncoding RNA called WISPER. This type of RNA does not produce proteins but may help regulate gene expression and cellular states. HAYA designed the therapy to reduce WISPER in cardiac myofibroblasts, thereby inhibiting pathological processes that promote scar formation and shifting the cells toward a healthier state.

WISPER’s use as a target for cardiac fibrosis stems from basic research published in 2017. At the time, the research team reported that it was enriched in cardiac fibroblasts and involved in fibrosis and cardiac remodeling in experimental models. However, a translational gap remains between inhibiting fibrosis in animal models and improving exercise capacity, symptoms, or hospitalization risk in patients with hypertrophic cardiomyopathy.

HTX-001 is currently in a Phase 1a/1b trial. According to the study design disclosed by the company, the trial first evaluates multiple ascending doses in healthy volunteers and then enrolls patients with nonobstructive hypertrophic cardiomyopathy, primarily assessing safety, tolerability, pharmacokinetics, and pharmacodynamics. The first cohort completed dosing in May this year. At this stage, no human efficacy data are available to determine whether reducing WISPER can actually decrease myocardial fibrosis.

The appeal of this development path is that it does not merely address heart rate, filling pressure, or other symptoms, but directly challenges the fibrotic mechanism underlying myocardial stiffness and remodeling. For symptomatic patients with nonobstructive disease, existing options are relatively limited. How improvements in imaging and biomarkers can be translated into functional gains that patients can genuinely feel remains a central question that new therapies must answer.

At present, the only information about this event comes from HAYA’s corporate announcement, with no public FDA documents or independent sources providing further details. Fast Track designation can be granted on the basis of early clinical or even nonclinical data, so the key tests for HTX-001 remain in subsequent trials: whether long-term suppression of WISPER is safe, whether the drug can effectively reach the relevant cardiac cells, and whether changes in fibrosis markers can deliver measurable clinical benefits.